Podoviridae Bacteriophage Composition for Drug-Resistant E. Coli

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing treatments for pathogenic Escherichia coli infections, such as antibiotics, are becoming less effective due to antibiotic resistance, and there is a need for alternative methods that can selectively target and inhibit the proliferation of these bacteria without affecting commensal bacteria.

Innovation Solution

A composition containing the Podoviridae bacteriophage Esc-COP-30, which specifically targets and lyzes pathogenic Escherichia coli, including strains like enterohemorrhagic, enterotoxigenic, enteroinvasive, enteropathogenic, and enteroaggregative Escherichia coli, using a pharmaceutically acceptable carrier and optionally additional bacteriophages, formulated into various dosage forms.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If antibiotics are used to treat pathogenic Escherichia coli infections, then antibacterial effect is achieved, but antibiotic resistance increases and effectiveness decreases

Engineering Contradiction:

Improveantibacterial effectivenessVSAvoidantibiotic resistance

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the fundamental parameter of antibacterial treatment from chemical antibiotics to biological bacteriophages. This parameter change bypasses the mechanism of antibiotic resistance by using a completely different mode of action - bacteriophages infect and replicate within bacteria to lyse them, rather than inhibiting bacterial cell processes with chemicals that bacteria can resist through genetic mutations.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent converts the previously harmful effect of bacteriophage specificity (limiting broad-spectrum coverage) into a beneficial feature by selecting and combining specific bacteriophages that target resistant E. coli strains. The high specificity that once limited utility is now transformed into precise targeting capability against antibiotic-resistant pathogens while sparing beneficial microbiota.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

2Reliability

If conventional antibiotics are used for bacterial treatment, then antibacterial coverage is achieved, but normal microflora is disturbed

Engineering Contradiction:

Improveantibacterial coverageVSAvoiddisturbance of normal microflora

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies local quality by using bacteriophages with highly specific host ranges that target only particular E. coli strains. Each bacteriophage is selected or engineered to recognize specific surface structures on pathogenic E. coli, allowing localized antibacterial action against the pathogen while leaving other bacterial species and commensal flora unaffected. This spatial and biological specificity resolves the contradiction between effective coverage and microbiota preservation.

Inventive Principle:

Principle #3Local quality

3Measurement precision

If bacteriophages are used to target specific bacteria, then selectivity is improved, but broad-spectrum activity is limited

Engineering Contradiction:

Improvebacterial targeting specificityVSAvoidbroad-spectrum antibacterial activity

Core Design Contradiction:

Measurement precisionVSAdaptability or versatility

Solution Approach 1:

The patent merges multiple individual bacteriophages with different specificities into a combination therapy formulation. By combining several bacteriophages that each target different E. coli strains or bacterial surface structures, the composition achieves both high specificity for pathogenic E. coli and broad-spectrum coverage across multiple E. coli pathotypes. This merging strategy resolves the contradiction by aggregating narrow-specificity agents into a broad-spectrum preparation.

Inventive Principle:

Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition effectively inhibits the proliferation of pathogenic Escherichia coli, reducing the risk of side effects on commensal bacteria and providing broad-spectrum antibacterial activity against specific strains, including cancer prevention and treatment.

Implementation Method 1

Once a bacteriophage infects a bacterial cell, the bacteriophage is proliferated inside the bacterial cell. After proliferation, the progeny of the bacteriophage destroys the bacterial cell wall and escapes from the host bacteria, suggesting that the bacteriophage has the ability to kill bacteria.

Methodology Applied

Scientific EffectBacteriophage lysis:

Data Source

PatentEP4161543B1Compositions and methods for inhibiting the proliferation of pathogenic escherichia coli

Publication Date: 2026.01.28 INTRON BIOTECHNOLOGY INC

Figure 1
Figure 2
Figure 3

AI summary

A composition for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes a Podoviridae bacteriophage (Esc-COP-30) having an ability to lyse the pathogenic Escherichia coli and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes administering to a subject a Podoviridae bacteriophage and lysing the pathogenic Escherichia coli by the Podoviridae bacteriophage.